Artiva Biotherapeutics 1 article

The cell-therapy profile of Artiva Biotherapeutics includes allogeneic NK cell therapy, while off-the-shelf natural killer cells supplies a more specific engineering or disease context. Its cell-therapy architecture extends from antibody-combination NK therapy to B-cell autoimmune disease cell therapy, with hematologic malignancy immunotherapy shaping potency, persistence, targeting or immune compatibility. GenoMethods keeps the cell-therapy modality and individual cellular products separate; the platform identity of Artiva Biotherapeutics also includes cryopreserved donor-derived NK cells.